{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T07:06:45Z","timestamp":1774681605916,"version":"3.50.1"},"reference-count":19,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,9,22]],"date-time":"2015-09-22T00:00:00Z","timestamp":1442880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Pain"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The receptor for advanced glycation end products (\n                      <jats:styled-content style=\"fixed-case\">RAGE<\/jats:styled-content>\n                      ) is a multi\u2010ligand receptor in the immunoglobulin superfamily.\n                      <jats:styled-content style=\"fixed-case\">RAGE<\/jats:styled-content>\n                      is localized throughout ascending sensory pathways (skin, peripheral nerve, dorsal root ganglion, spinal cord), and in cell types interacting with sensory neurons (endothelial cells, smooth muscle cells, monocytes and macrophages). Neuronal\n                      <jats:styled-content style=\"fixed-case\">RAGE<\/jats:styled-content>\n                      expression increases in pathological pain states in humans and rodents, and soluble\n                      <jats:styled-content style=\"fixed-case\">RAGE<\/jats:styled-content>\n                      attenuates thermal hypoalgesia in diabetic mice. The objective of the present study was to investigate whether pharmacological modulation of\n                      <jats:styled-content style=\"fixed-case\">RAGE<\/jats:styled-content>\n                      could attenuate mechanical allodynia in rodent pain models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We developed an anti\u2010\n                      <jats:styled-content style=\"fixed-case\">RAGE<\/jats:styled-content>\n                      monoclonal antibody (11E6) that binds to the C\n                      <jats:sub>2<\/jats:sub>\n                      immunoglobulin domain of human\n                      <jats:styled-content style=\"fixed-case\">RAGE<\/jats:styled-content>\n                      , binds to mouse RAGE, and presumably to the same domain in mouse RAGE. The antinociceptive activity of 11E6 was investigated in mouse models of inflammatory (complete Freund's adjuvant) and neuropathic (chronic constriction injury of the sciatic nerve) pain. Mice were dosed intraperitoneally with 11E6 or IgG (negative control).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Increased mechanical thresholds were observed following a single dose of 11E6 in both inflammatory and neuropathic pain models. Similar treatment with IgG did not alter nociceptive sensitivity. Repeated dosing with 11E6 significantly attenuated established mechanical hypersensitivity in a neuropathic pain model in a dose\u2010related fashion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      These data demonstrate that specific modulation of\n                      <jats:styled-content style=\"fixed-case\">RAGE<\/jats:styled-content>\n                      effectively attenuates nociceptive sensitivity associated with chronic inflammatory and neuropathic pain states.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejp.775","type":"journal-article","created":{"date-parts":[[2015,9,22]],"date-time":"2015-09-22T04:47:29Z","timestamp":1442897249000},"page":"607-614","source":"Crossref","is-referenced-by-count":21,"title":["A monoclonal antibody against the receptor for advanced glycation end products attenuates inflammatory and neuropathic pain in the mouse"],"prefix":"10.1002","volume":"20","author":[{"given":"J.\u2010D.","family":"Brederson","sequence":"first","affiliation":[{"name":"AbbVie, Inc. Neuroscience Research North Chicago USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Strakhova","sequence":"additional","affiliation":[{"name":"AbbVie, Inc. Neuroscience Research North Chicago USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Mills","sequence":"additional","affiliation":[{"name":"AbbVie, Inc. Neuroscience Research North Chicago USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Barlow","sequence":"additional","affiliation":[{"name":"AbbVie Bioresearch Center Global Biologics 100 Research Drive Worcester USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Meyer","sequence":"additional","affiliation":[{"name":"Neuroscience Discovery Abbvie Deutschland GmbH &amp; Co. KG Ludwigshafen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Nimmrich","sequence":"additional","affiliation":[{"name":"Neuroscience Discovery Abbvie Deutschland GmbH &amp; Co. KG Ludwigshafen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Leddy","sequence":"additional","affiliation":[{"name":"AbbVie Bioresearch Center Global Biologics 100 Research Drive Worcester USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Simler","sequence":"additional","affiliation":[{"name":"AbbVie, Inc. Neuroscience Research North Chicago USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"AbbVie Bioresearch Center Global Biologics 100 Research Drive Worcester USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Jarvis","sequence":"additional","affiliation":[{"name":"AbbVie, Inc. Neuroscience Research North Chicago USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Lacy","sequence":"additional","affiliation":[{"name":"AbbVie Bioresearch Center Global Biologics 100 Research Drive Worcester USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,9,22]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2014.06.199"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3959(88)90209-6"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI18058"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-005-0688-7"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-0270(94)90144-9"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.20.040180.002301"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.2.379"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-005-1043-3"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.10.1163"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2013.07.008"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1433.059"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-004-0160-0"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2013.11.001"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwi053"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/03009740510026715"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2010.03.023"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s001250050839"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161208784139774"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63909-0"}],"container-title":["European Journal of Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejp.775","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ejp.775","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T09:57:43Z","timestamp":1753351063000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ejp.775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,22]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1002\/ejp.775"],"URL":"https:\/\/doi.org\/10.1002\/ejp.775","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725804860.793523400","asserted-by":"object"}]},"ISSN":["1090-3801","1532-2149"],"issn-type":[{"value":"1090-3801","type":"print"},{"value":"1532-2149","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,22]]}}}